(USD) | Jun 2024 | Q/Q |
---|---|---|
Revenue | 702.1MM | +1% |
Gross Profit | 230MM | -0% |
Cost Of Revenue | 472.1MM | +1% |
Operating Income | 126.2MM | +3% |
Operating Expenses | 103.8MM | - |
Net Income | 111.3MM | -3% |
R&D | 17.5MM | -1% |
G&A | 83MM | -4% |
Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
West Pharmaceutical (WST) delivered earnings and revenue surprises of -14.12% and 4.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Exton, Pennsylvania-based company said it had profit of $1.51. Earnings, adjusted for amortization costs, were $1.52 per share. The results missed Wall Street expectations.
West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance.
West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund’s Investor Class fund ARTMX returned -5.73%, Advisor Class fund APDMX posted a return of -5.67%, and Institutional Class fund APHMX returned -5.64%, compared […]
West Pharmaceutical Services, Inc. ( NYSE:WST ) received a lot of attention from a substantial price movement on the...
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.